HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Idiopathic erythrocytosis: a disappearing entity.

Abstract
Erythrocytosis results when there is an increased red cell mass and thus an increased hemoglobin. The causes can be divided into primary intrinsic defects of the erythroid progenitor cell and secondary defects, where factors external to the erythroid compartment are responsible. Both can then be further divided into congenital and acquired categories. Congenital causes include mutations of the erythropoietin receptor and defects of the oxygen-sensing pathway including VHL, PHD2 and HIF2A mutations. When fully investigated there remain a number of patients in whom no cause can be elucidated who are currently described as having idiopathic erythrocytosis. Investigation should start with a full history and examination. Having eliminated the common entity polycythemia vera, further direction for investigation is guided by the erythropoietin level. Clinical consequences of the various erythrocytoses are not clear, but in some groups thromboembolic events have been described in young patients. Evidence is lacking to define best management, but aspirin and venesection to a target hematocrit should be considered.
AuthorsMary Frances McMullin
JournalHematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program (Hematology Am Soc Hematol Educ Program) Pg. 629-35 ( 2009) ISSN: 1520-4383 [Electronic] United States
PMID20008248 (Publication Type: Journal Article, Review)
Chemical References
  • Platelet Aggregation Inhibitors
  • Receptors, Erythropoietin
  • Erythropoietin
  • Aspirin
Topics
  • Adult
  • Anoxia (blood, genetics, physiopathology)
  • Aspirin (therapeutic use)
  • Blood Viscosity
  • Diagnosis, Differential
  • Erythropoiesis
  • Erythropoietin (deficiency, pharmacology, secretion)
  • Female
  • Hematocrit
  • Humans
  • Male
  • Mutation
  • Phlebotomy
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Polycythemia (classification, congenital, diagnosis, drug therapy, epidemiology, therapy)
  • Polycythemia Vera (diagnosis)
  • Receptors, Erythropoietin (genetics)
  • Signal Transduction
  • Thrombophilia (drug therapy, etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: